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OBJECTIVE: To determine peroxisome proliferator activated receptor a and g mRNA expression in liver tissue of
hepatitis C virus-infected patients with and without human immunodeficiency virus and its possible
contribution to an acceleration of liver disease progression.
METHODS: We measured peroxisome proliferator-activated receptor a and g mRNA expression by real-time
polymerase chain reaction in liver tissues from 40 subjects infected only with hepatitis C virus, 36 subjects
co-infected with hepatitis C virus and human immunodeficiency virus and 11 normal adults.
RESULTS: Hepatic mRNA expression of both peroxisome proliferator-activated receptors was significantly lower
in hepatitis C virus-infected subjects with and without human immunodeficiency virus co-infection compared to
the controls. Non-black race was also identified as a predictor of lower peroxisome receptor a and g mRNA
expression. Compared to subjects infected only with hepatitis C virus, liver peroxisome receptor g mRNA
expression was significantly lower in hepatitis C virus/human immunodeficiency virus-co-infected subjects
(0.0092 in hepatitis C virus/human immunodeficiency virus-co-infection vs. 0.0120 in hepatitis C virus-only;
p=0.004). Hepatic peroxisome receptor amRNA expression in the hepatitis C virus-infected patients was lower in
the presence of human immunodeficiency virus co-infection in non-black subjects (0.0769 vs. 0.1061; p=0.02),
whereas the levels did not vary based on human immunodeficiency virus status among black subjects.
CONCLUSION: mRNA expression of both peroxisome proliferator-activated receptors is impaired in hepatitis C
virus-infected liver and further reduced by human immunodeficiency virus co-infection, although the
suppressive effects of the viruses are substantially mitigated in black patients.
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’ INTRODUCTION
Chronic hepatitis C virus (HCV) infection in the setting of
human immunodeficiency virus (HIV) co-infection is char-
acterized by accelerated liver disease, although the under-
lying reasons are unclear (1). Activation of peroxisome
proliferator-activated receptor (PPAR) a and g, members of
the nuclear receptor superfamily, inhibits the expression of
inflammatory cytokines and chemokines and reduces hepatic
inflammatory processes (2). Additionally, PPARg activation
maintains a quiescent hepatic stellate cell phenotype and
decreases pro-fibrogenic products (2). The HCV core protein
reduces the expression of hepatic PPARa in HCV mono-
infected patients (3). The role of PPARg in the pathogenesis
of HCV-related liver disease is less clear because the data are
conflicting (2-5). Decreased expression of PPARg mRNA has
been reported in liver biopsies of HIV-infected subjects with
insulin resistance and unexplained liver enzyme elevation
(6), suggesting an effect of HIV on liver PPARg expression.DOI: 10.6061/clinics/2015(12)05
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This result is supported by several in vitro and in vivo studies
that reported evidence for HIV infection of the liver (7).
We hypothesized that HIV infection reduces the expres-
sion of PPARa in the HCV-infected liver. We also hypothe-
sized that reduced PPARa and PPARg expression would
accelerate the process of liver fibrosis in patients with HIV/
HCV co-infection.
’ METHODS
We conducted a multicenter, comparative, cross-sectional
study that included liver tissue samples from HCV-only
infected, HCV/HIV-co-infected and HCV/HIV-uninfected con-
trol subjects. The local institutional review boards (IRB)
approved the research project. Informed consent was obtained
from each patient included in the study and the study protocol
conformed to the ethical guidelines of the 1975 Declaration of
Helsinki as reflected in an a priori approval by the institution’s
human research committee. The participating centers were
Wake Forest University Health Sciences, Winston Salem, NC,
USA, Unidade de Referência em Doenc¸as Infecciosas, Facul-
dade de Medicina do ABC, Santo André, São Paulo, Brazil,
Hospital das Clínicas, Faculdade de Medicina da Universidade
de São Paulo, São Paulo, Brazil, and Istituto Malattie Infettive,
University of Sassari, Sassari, Italy.
Selection of subjects
Subjects chronically infected with HCV, with or without
concurrent HIV co-infection, who were 18 years of age or older
were eligible for the study. Active HCV or HIV infection was
defined as detectable plasma HCV RNA or a positive anti-HIV
antibody titer at the time of enrollment, respectively. Subjects
were excluded if other causes of liver disease were present,
including hepatitis B virus (HBV) co-infection (HBsAg positive),
hemochromatosis, autoimmune hepatitis, Wilson’s disease, or
alpha1-antitrypsin deficiency. Alcohol intake was not an exclu-
sion criterion, but the amount consumed was specified as
accurately as possible based on patient reports. Liver samples
from 11 HIV- and HCV-uninfected control subjects that were
previously collected as part of another IRB-approved study at
Wake Forest University Health Sciences were used for compara-
tive analysis. At the time of collection, the control subjects had
screened negative for other known liver diseases. However, no
clinical or demographic data were available for these subjects.
Data collection
Data were collected from medical records and included age,
sex, weight, body mass index (BMI; kg/M2), race, country of
origin, HCV genotype, serum HCV RNA, alanine amino-
transferase (ALT) and aspartate aminotransferase (AST)
levels, liver biopsy data (fibrosis, inflammation, and stea-
tosis), absolute and % CD4+ lymphocytes, HIV RNA serum
levels, highly active antiretroviral therapy (HAART) at the
time of liver biopsy, diabetes mellitus (DM) status, alcohol
intake, and serum cholesterol and triglyceride levels. Data
from liver biopsies included METAVIR scores for fibrosis
(F0 = no fibrosis, F1 = portal fibrosis without septa, F2 =
portal fibrosis with few septa, F3 = numerous septa without
cirrhosis, and F4 = cirrhosis), inflammation (‘activity score’ of
A0 = no activity, A1 = mild activity, A2 = moderate activity, and
A3 = severe activity), and steatosis scored as used in non-alcoholic
fatty liver disease (o5%, none, 5-33%, mild, 34-66%, moderate,
and 466%, severe).
Tissue Preparation
All HCV-infected or HCV/HIV-co-infected subjects under-
went liver biopsies as part of the routine medical care for their
liver disease according to local practices. A portion of each
biopsy was stored immediately in RNA stabilizing solution
(RNAlater, Ambion, Austin, TX, USA) according to the package
insert. Total RNA was extracted from the liver biopsies using
RNA STAT-60 Reagent (Tel-Test, Friendswood, TX, USA) ac-
cording to the manufacturer’s protocol. Briefly, liver tissues were
homogenized in RNA STAT-60. Then, chloroform was added
and the samples were centrifuged to separate the homogenate
into two phases. The upper aqueous phase was transferred to a
nuclease-free tube and mixed with isopropanol, and the RNA
was precipitated overnight at -20oC. After centrifugation, the
RNA pellet was washed with 75% ethanol, briefly air dried and
re-suspended in nuclease-free water. The quality of the RNAwas
confirmed using the Agilent Bioanalyzer system.
Quantification of PPARa and PPARg mRNA
expression by RT-PCR
Two micrograms of RNAwas reverse-transcribed to cDNA
using the Applied Biosystems High Capacity RNA to cDNA
Kit (Applied Biosystems, Foster City, CA, USA). PPARa,
PPARg, and GAPDH expression was assessed by real-time
PCR (RT-PCR) using pre-formulated TaqMan Gene Expres-
sion Assays for each gene (Applied Biosystems, Foster City,
CA, USA) composed of two unlabeled primers and a FAM
dye-labeled MGB probe designed to span introns and avoid
the amplification of genomic DNA. The RT-PCR results were
calculated using the comparative Ct method based on
relative gene expression compared to GAPDH.
Statistical methods
The primary outcome of the study was the analysis of
comparative mRNA expression of PPARa and PPARg in the
livers of HCV-only versus HCV/HIV-co-infected subjects.
Based on a previous report in HCV-infected subjects in which
the mean PPARa level was 1.8 and the standard deviation was
2.8 (7), 39 individuals were needed in each group to rule out
equivalence of the means (HCV and HCV/HIV groups) and
to obtain a desired power of 80% and two-sided significance
level of 5%. Eleven samples from subjects negative for viral
hepatitis were included for comparison (control group).
The results are presented in absolute numbers for con-
tinuous variables and in proportions for categorical variables.
Comparisons between groups were performed using Fisher’s
exact test for categorical variables and the t or ANOVA test
for continuous variables. Univariate and multivariate linear
regression analyses were performed to identify independent
outcome predictor factors of PPARa and PPARg. All p-values
o0.05 were considered statistically significant. Statistical
Package for the Social Sciences (SPSS), version 20.0 (SPSS
Inc, Chicago, IL, USA) was used for statistical analysis.
’ RESULTS
We were able to obtain adequate liver samples for the
study from 40 HCV-only infected and 36 HCV/HIV-
co-infected subjects. The characteristics of the subjects are
summarized in Table 1. Demographics were similar between
the two groups with the exception of race and country of
origin. There were more white subjects in the HCV-only
infected group. Serum HCV RNA levels were higher and
ALT levels were lower in the HCV/HIV-co-infected group,
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whereas the inflammation and fibrosis METAVIR scores
were comparable. The HCV/HIV-co-infected subjects had
significantly higher triglyceride levels compared to the HCV-
only infected subjects. All HIV-infected subjects had CD4
counts 4200 cells/mm3 and 98% were receiving HAART.
Quantification of PPARa mRNA expression
by RT-PCR
Based on RT-PCR analyses of liver samples, controls had
higher PPARa mRNA expression levels compared to both
the HCV-only (p=0.001) and HCV/HIV-co-infected subjects
(p=0.0001) (Figure 1A). The expression levels were compar-
able between the HCV-only and HCV/HIV-co-infected
subjects (0.1178 vs. 0.0931; p=0.1). In both HCV-infected
groups, the PPARa levels were higher among subjects from
the United States (US) compared to non-US subjects (p=0.02).
There were also differences in PPARa mRNA expression
based on race, with black subjects having a significantly
higher expression level compared to non-black subjects
(0.1381 vs. 0.0946; p=0.02). Given these racial differences,
additional analyses were performed to compare HCV-only
infected and HCV/HIV-co-infected subjects stratified by
race. A significantly lower level of PPARa mRNA expression
Table 1 - Characteristics of the patients according to HIV status*.
HCV-Only HCV & HIV p-value
N 40 36 ---
Age 47 (28-69) 49 (36-68) 0.4
Male sex 29 (72.5) 24 (67) 0.4
Weight 82 (53-130) 75 (51-121) 0.2
BMI 28 (18-36) 26 (17-37) 0.3
Race 0.003
White 29 (72.5) 12 (33)
Black 6 (15) 14 (39)
Mixed/Hispanic 4 (10) 10 (28)
Native American 1 (2.5) 0
Country o0.0001
Brazil 9 (22.5) 21 (58)
Italy 12 (30) 0
USA 19 (47.5) 15 (42)
HCV genotype 0.5
1 34 (94) 30 (91)
2 0 1 (3)
3 1 (3) 2 (6)
4 1 (3) 0
HCV RNA, log10 5.82 (3.16-7.00) 6.17 (5.1-7.59) 0.04
ALT 100 (15-351) 62 (15-213) 0.02
AST 93 (20-1,018) 47 (16-103) 0.1
METAVIR fibrosis score 0.6
F0 4 (10) 6 (17)
F1 14 (350 14 (39)
F2 14 (35) 13 (36)
F3 5 (12.5) 2 (5)
F4 3 (7.5) 1 (3)
METAVIR inflammation score 0.3
A0 1 (2.5) 5 (14)
A1 17 (42.5) 15 (42)
A2 17 (42.5) 11 (30)
A3 5 (12.5) 5 (14)
Steatosis 0.4
Unknown 9 (22.5) 7 (19.5)
None 18 (45) 19 (53)
Mild 6 (15) 8 (22)
Moderate 4 (10) 1 (3)
Severe 3 (7.5) 1 (3)
CD4 --- 540 (260-1049) ---
CD4% --- 27 (15-44) ---
HIV RNA --- 177 (o50-1450) ---
HAART
No --- 3 (8) ---
AZT --- 11 (68) ---
Dideoxynucleosides --- 2 (6) ---
PI --- 20 (59) ---
DM --- 6 (17) 0.2
Current alcohol use --- 9 (26) 0.4
Cholesterol levels 169 (113-231) 159 (91-226) 0.4
Triglyceride levels 83 (37-2091 149 (55-428) 0.003
*Mean (range) unless otherwise stated.
BMI: body mass index; HCV: hepatitis C virus; HIV: human immunodeficiency virus; ALT: alanine aminotransferase; AST: aspartate aminotransferase;
HAART: highly active antiretroviral therapy; AZT: azidothymidine; PI: protease inhibitor; DM: diabetes mellitus.
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was found among non-black subjects in the HCV/HIV-
co-infected group compared to the HCV-only group (0.0769
vs. 0.1061; p=0.02) (Figure 1B), whereas there were no
differences among black subjects (p=0.2) (Figure 1C). Other
factors that were evaluated and found to have no association
with PPARa gene expression included age, sex, BMI, HCV
genotype, HCV RNA serum levels, DM, alcohol use, CD4
counts, serum HIV RNA levels and HAART therapy. In a
multivariate linear regression model in which HIV status,
black race, and country of origin were included, all three
factors lost statistical significance. The pathology results
demonstrated that moderate-to-severe inflammation was
associated with lower PPARa mRNA expression among
non-black, non-HIV subjects (0.0868 in METAVIR A2/A3
subjects vs. 0.1255 in A0/A1 subjects; p=0.01), but no
associations were detected in the remaining groups.
Quantification of PPARg mRNA expression
by RT-PCR
RT-PCR analysis of PPARg mRNA in the liver samples
indicate that the controls had a higher level of expression
compared to both the HCV-only infected (p=0.01) and HCV/
HIV-co-infected subjects (p=0.001) (Figure 2A). The expression
levels were significantly higher in the HCV-only-infected
subjects compared to the HCV-HIV-co-infected subjects (0.0120
vs. 0.0092; p=0.004). In both HCV-infected groups, PPARg levels
were higher among US subjects compared to non-US subjects
(p=0.04). There were also differences in PPARg expression based
on race, with black subjects having a significantly higher
expression level compared to non-black subjects (0.0101 vs.
0.0125; p=0.03). However, there was a significantly lower level of
PPARg mRNA expression in HCV-HIV-co-infected subjects
compared to HCV-only subjects in both groups [non-black
(p=0.001) (Figure 2B) and black subjects (p=0.03)] (Figure 2C).
Other factors evaluated and found to have no association with
PPARg gene expression include age, sex, BMI, HCV genotype,
HCV RNA serum levels, DM, alcohol use, CD4 counts, serum
HIV RNA levels and HAART therapy (Table 2). In multivariate
linear regression analyses, only HIV-co-infection (p=0.001) and
non-black race (p=0.04) were independently associated with
lower PPARg expression (Table 2). The pathology findings
demonstrated that more advanced fibrosis in liver biopsy was
associated with lower hepatic PPARgmRNA expression among
non-black, non-HIV subjects (METAVIR score F2/F3/F4 0.0102
vs. METAVIR score F0/F1 0.0126; p=0.04). There was no
association between PPARg mRNA expression and steatosis in
any group.
’ DISCUSSION
Our results show that hepatic PPARa and PPARg mRNA
expression levels were reduced in the presence of HCV
infection. Surprisingly, we observed marked differences by
ethnicity; as a result, the power of the study to detect
differences based on HIV status was diminished to a large
extent, especially with regard to PPARa. To the best of our
Figure 1 - Quantification of liver peroxisome proliferator-activated receptor a mRNA expression by RT-PCR. (A) All patients: control
(n=11), hepatitis C virus (n=40), and hepatitis C virus-HIV subjects (n=36) (error bars represent standard deviations). (B) Only non-black
subjects: hepatitis C virus and hepatitis C virus-HIV subjects (p=0.02). (C) Only black subjects: hepatitis C virus and hepatitis C virus-HIV
subjects (p=0.2).
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knowledge, this is the first report to examine or identify
differences in PPARa and PPARg liver expression by race. Our
results suggest that genetic polymorphisms linked to ethnicity
may explain this finding. Notably, PPAR has been implicated in
the pathogenesis of hepatic steatosis, which has been reported
to be less frequent among black subjects (8-10). Nevertheless,
the non-black group is very heterogeneous because it includes
Caucasians and mixed ethnicities, especially among subjects
from Brazil. Because the liver samples were obtained from
diverse races and different countries, we could not exclude the
possibility that nutritional or other environmental factors might
have had an effect on liver PPARa and/or PPARg expression.
In line with previous reports, PPARa gene expression was
impaired in the livers of HCV-infected subjects (3,4,11,12). Our
data indicate that HIV infection also decreased PPARa gene
expression, as revealed in non-black subjects. However, the
effect of HIV was mitigated in black patients, suggesting that
this group might be less vulnerable to the effects of the HIV
virus on PPARa expression.
PPARa plays a pivotal anti-inflammatory role in hepato-
cytes (2,13). More severe liver inflammation in HCV-infected
subjects with reduced PPARa expression in hepatocytes has
been reported by some but not all authors (3,4,12). In our
study, an inverse correlation between PPARa expression and
necroinflammatory activity was only observed in the non-
black HCV-only infected group based on METAVIR scores,
a method that is likely inadequate for the detection of subtle
trends in HIV-related fibrosis in HCV-infected patients.
Larger studies with a more homogeneous population using
a more precise method of inflammation measurement might
shed additional light on this subject.
In contrast with prior reports, PPARg gene expression was
reduced in the livers of HCV-infected subjects compared to the
controls (3,12). PPARg expression in HCV-infected livers was
further reduced by HIV co-infection. PPARg is primarily
expressed in hepatic stellate cells and its expression disappears
when these cells undergo myofibroblastic differentiation and
fibrogenesis (14). There appears to be a critical role for PPARg
in liver fibrogenesis, and treatment of hepatic stellate cells with
synthetic PPARg suppresses the fibrogenetic process (2,5). In
our study, an inverse correlation was observed between PPARg
expression and more advanced fibrosis in the non-black HCV-
only-infected group. The limitations of the present study can be
overcome by measuring liver fibrosis using other methods,
such as morphometric image analysis or quantification of
fibrosis proteins and using a larger, more homogeneous
population (9,15).
Our findings suggest that genetic polymorphisms may
determine the expression of PPARa and PPARg in the liver
and that the impairment induced by the HCVand HIV viruses
is mitigated in subjects of black ethnicity. Genetic studies are
needed to determine why hepatic expression of these nuclear
Figure 2 - Quantification of liver peroxisome proliferator-activated receptor g mRNA expression by RT-PCR. (A) All patients: control
(n=11), hepatitis C virus (n=40), and hepatitis C virus-HIV subjects (n=36) (error bars represent standard deviations). (B) Only non-black
subjects: hepatitis C virus and hepatitis C virus-HIV subjects (p=0.001). (C) Only black subjects: hepatitis C virus and hepatitis C virus-HIV
subjects (p=0.03).
794
HIV and Hepatic PPAR Expression
Shores NJ et al.
CLINICS 2015;70(12):790-796
receptors differs by race. Despite the complexity introduced
by race, PPARa and PPARg hepatic expression were affected
by HIV infection. PPARa expression is most robust in
hepatocytes, although it is also expressed in other cell types.
Hepatocytes have not been demonstrated to be infected by
HIV, although HIV-1 has been proposed to be present in the
liver and can promote fibrosis, most likely through indirect
effects on hepatocytes (7,16). There is evidence from studies
using cell lines that HIV may infect human stellate cells (17).
The reduction in PPARg expression, which is more abundant
in stellate cells, might be due to direct infection by HIV. HIV
may also affect PPARa and PPARg expression via immune
activation and the disruption of cellular functions.
Despite some limitations of our study, including lack of
adequate samples to test protein expression, small sample
size, ethnic and HCV genotype diversity of the subjects, and
lack of a more refined measurement of liver inflammation
and fibrosis, several findings are intriguing and deserve
further attention. Additional studies are needed to elucidate
the mechanisms underlying the decreased hepatic PPARa
and PPARg mRNA expression observed in our study. Thus,
larger studies on HCV/HIV-co-infected individuals stratified
by ethnicity and the inclusion of mRNA/protein expression
of other genes associated with inflammation and fibrogenesis
would shed light on these results. Further studies of genetic
polymorphisms linked to ethnicity are also warranted to
explain the differences in the expression of these PPARs.
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Table 2 - PPARa mRNA expression: univariate and multivariate linear regression analyses.
Univariate analyses Beta (95% CI); p-value Multivariate Analysis Beta (95% CI); p-value
HIV+ -0.175 ((-0.057) - (-0.007)); 0.1 -0.225 ((-0.064) - (0.001)); p=0.06
Age -0.086(-0.003 - 0.001); 0.4
Male sex -0.209 ((-0.067) - (0.003); 0.07
BMI 0.067 (-0.003 - 0.005); 0.6
Black race 0.272 (0.008 – 0.079); 0.02 0.225 (-0.008 - 0.080); 0.1
United States 0.333 (0.016 - 0.078); 0.003 0.197((-0.010) - 0.065)); 0.1
HCV-1 genotype 0.216 ((-0.006) - (0.126); 0.07
HCV RNA -0.144 (0.000 - 0.000); 0.3
METAVIR F3/F4 -0.112((-0.068) - (0.024); 0.3
METAVIR A2/A3 0.063 ((-0.024) – (0.041)); 0.6
Steatosis (yes vs. no) -0.105 ((-0.057) – (0.024)); 0.4
DM 0.054 ((-0.04) – (0.063)); 0.6
Alcohol use 0.120 ((-0.017) - (0.055)); 0.3
CD4 counts -0.235 (0.000 - 0.000); 0.3
HIV RNA levels 0.112 (0.000 - 0.000); 0.7
HAART regimen
AZT -0.337 ((-0.029) – (0.000)); 0.051
Dideoxynucleosides 0.029 ((-0.090) – (0.016)); 0.9
PI -0.038 ((-0.052) - 0.042); 0.8
BMI: body mass index; HCV: hepatitis C virus; HAART: highly active antiretroviral therapy; AZT: azidothymidine; PI: protease inhibitor; DM: diabetes
mellitus.
Table 3 - PPARg mRNA expression: univariate and multivariate linear regression analyses.
Univariate analyses Beta (95% CI); p-value Multivariate Analysis Beta (95% CI); p-value
HIV+ -0.330 ((-0.005) - (-0.001)); 0.004 -0.392 ((-0.005) - (-0.001)); p=.001
Age -0.142 (0.000 - 0.000); 0.2
Male sex -0.046 ((-0.003) - (0.002); 0.7
BMI 0.085 (0.000 - 0.000); 0.9
Black race 0.25 (0.000 – 0.005); 0.03 0.266 (0.000 - 0.005); 0.04
United States 0.333 (0.001 - 0.005); 0.003 0.166 ((-0.001) - 0.004)); 0.2
HCV-1 genotype 0.133((-0.002) - (0.006); 0.3
HCV RNA -0.109 (0.000 - 0.000); 0.4
METAVIR F3/F4 -0.08 ((-0.004) - (0.002); 0.5
METAVIR A2/A3 0.128 ((-0.001) – (0.003)); 0.9
Steatosis (yes vs. no) -0.051 ((-0.003) – (0.002)); 0.7
Diabetes 0.056 ((-0.002) – (0.004)); 0.6
Alcohol use 0.065 ((-0.002) - (0.003)); 0.5
CD4 counts -0.07 (0.000 - 0.000); 0.7
HIV RNA levels -0.017 (0.000 - 0.000); 0.9
HAART regimen
AZT -0.297 ((-0.005) – (0.000)); 0.09
Dideoxynucleosides -0.022 ((-0.006) – (0.005)); 0.9
PI -0.06 ((-0.003) - 0.002); 0.7
BMI: body mass index; HCV: hepatitis C virus; HAART: highly active antiretroviral therapy; AZT: azidothymidine; PI: protease inhibitor; DM: diabetes
mellitus.
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